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Abstract
Background: There have been only limited studies assessing the economic burden of HIV/AIDS in terms of direct
costs, and there has been no published study related to productivity costs in Nepal. Therefore, this study explores
in detail the economic burden of HIV/AIDS, including direct costs and productivity costs. This paper focuses on the
direct costs of seeking treatment, productivity costs, and related factors affecting direct costs, and productivity costs.
Methods: This study was a cross-sectional, quantitative study. The primary data were collected through a structured
face-to-face survey from 415 people living with HIV/AIDS (PLHIV). The study was conducted in six representative
treatment centres of six districts of Nepal. The data analysis regarding the economic burden (direct costs and
productivity costs) was performed from the household’s perspective. Descriptive statistics have been used, and
regression analyses were applied to examine the extent, nature and determinants of the burden of the disease,
and its correlations.
Results: Average total costs due to HIV/AIDS (the sum of average total direct and average productivity costs
before adjustment for coping strategies) were Nepalese Rupees (NRs) 2233 per month (US$ 30.2/month), which
was 28.5% of the sample households’ average monthly income. The average total direct costs for seeking HIV/AIDS
treatment were NRs 1512 (US$ 20.4), and average productivity costs (before adjustment for coping strategies) were NRs
721 (US$ 9.7). The average monthly productivity losses (before adjustment for coping strategies) were 5.05 days per
person. The major determinants for the direct costs were household income, occupation, health status of respondents,
respondents accompanied or not, and study district. Health status of respondents, ethnicity, sexual orientation and
study district were important determinants for productivity costs.
Conclusions: The study concluded that HIV/AIDS has caused a significant economic burden for PLHIV and their
families in Nepal. The study has a number of policy implications for different stakeholders. Provision of social
support and income generating programmes to HIV-affected individuals and their families, and decentralising
treatment services in each district seem to be viable solutions to reduce the economic burden of HIV-affected
individuals and households.
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Background
An estimated 36.9 million people were living with human
immunodeficiency virus (HIV) or acquired immunodefi-
ciency syndrome (AIDS) in the world. An estimated num-
ber of 1.2 million people died and 2 million people were
newly infected by HIV/AIDS in a year [1]. Therefore,
HIV/AIDS is one of the major burdens of disease globally.
After the introduction of multiple antiretroviral therapy
(ART), HIV/AIDS became a chronic disease, and there is
a need to provide long-term care and support for the ill
person. HIV/AIDS is concentrated among adults of
working age, unlike other diseases [2, 3]. Long-term illness
due to HIV/AIDS demands a higher level of treatment
costs for the HIV-affected households. Therefore, HIV/
AIDS causes depletion of savings and productive assets,
and increases the indebtedness of the HIV-affected house-
holds [4]. Moreover, the higher health care expenditure of
the households reduces investment for nutritional food
for the family members, investment for farming or busi-
ness, and the education of the children. After the initiation
of ART medicine, mortality rates have reduced, but still a
considerable number of people (1.2 million) die due to
HIV/AIDS every year [1]. Death during the working age
of the victim is a major factor in the economic impact of
HIV/AIDS [5]. The household level impact of HIV/AIDS
includes direct costs, including medical and non-medical
costs, and productivity costs such as loss of labour time,
as a result of the morbidity of HIV positive household
members, as well as time spent by others caring for them
[6]. This evidence suggests that HIV/AIDS places signifi-
cant economic pressure on households trying to pay for
health care costs, and trying to make up for lost income.
If a member of a farming household is affected by
HIV/AIDS at a young and productive age, the household
either reduces the size of their farm due to the reduction
in the number of farm (family) workers [7] or hires ex-
ternal labour to work on their farm to replace the ill
family member and carer. Thus, there is a reduction in
the number of family workers and an increment in the
labour costs of the farm due to HIV/AIDS. HIV/AIDS
cannot only kill the economically active population but
will also destroy their experience; skills and knowledge
built up over a period of years [2]. If a breadwinner dies,
then the family struggles to cope, not only emotionally
but also economically. Poverty increases if the house-
hold’s head dies and scarce resources are utilised during
the period of ill health.
The financial coping mechanism for ill health plays an
important role in the economic impact experienced by
households [8]. Household income and savings, sale of
assets, loans, borrowing and removing children from
school are the major coping strategies used by HIV-
affected households [4, 9–13]. Sale of productive assets
like land, farm animals and farm equipment, directly
affect the productivity of households within a short
period, whilst loans, borrowing and removing children
from school affect the productivity of households over a
longer period. Moreover, the sale of property, like land
and homes for the treatment of HIV/AIDS, may render
HIV-affected household landless and/or homeless. The
financial coping strategies may solve the short-term
problems of the HIV-affected households but may also
reduce the economic capacity of the households in the
long run, and risk pushing them into further poverty.
Past studies about the economic impact of HIV/AIDS
have reported that the disease-affected households
generate relatively lower income than unaffected house-
holds [14, 15]: people living with HIV/AIDS (PLHIV)
are often forced to leave their employment or business
due to their illness [12]. The decline in health of the ill
person causes further impact on the household [9, 15].
The need for life-long treatment due to the chronic
nature of the disease can have life-long financial impli-
cations on such households [3].
Since the first case of HIV/AIDS was reported in
1988 in Nepal, the nature of the HIV epidemic has
gradually moved from being a ‘low prevalence’ to a
‘concentrated epidemic’ [16] among injecting drug
users, sex workers and migrant workers who travel
between Nepal and India. Over 85% of HIV in Nepal is
transmitted through sexual activities [17]. Out of 28
million of the Nepalese population [18], estimated
39,249 people are living with HIV/AIDS. However, the
recently reported cases of HIV/AIDS is 26,702, which
is 68% of the national estimates of HIV infection [17].
There is still a significant gap (32%) between officially
estimated, and medically reported cases. The HIV
prevalence among the adult population (age between
15–49 years) is officially estimated at 0.20% (adult
male 0.28%, adult female 0.13%), which is a decreasing
trend [16].
Lack of knowledge about health insurance or unavail-
ability of such insurance for HIV/AIDS causes higher
out-of-pocket payment for the disease-affected house-
holds in Nepal [19]. This evidence suggests that the eco-
nomic impact of HIV/AIDS can be catastrophic to the
HIV-affected households [20].
Poverty is an important factor in the propagation of
HIV/AIDS. Poor people are more vulnerable for many
reasons, including exposure to high-risk behaviours and
poor access to health services [21]. HIV/AIDS and
poverty are interconnected in a vicious circle [22, 23].
It is believed that HIV/AIDS causes poverty and
worsens already existing poverty [24]. The effect of
HIV/AIDS is especially severe on households, which
are already in poverty [13, 25]. Moreover, there is no or
very little social security (such as financial allowances) in
developing countries such as Nepal. Therefore, HIV/AIDS
Poudel et al. BMC Health Services Research  (2017) 17:76 Page 2 of 13
has a severe economic impact on HIV-affected house-
holds in developing countries compared to developed
countries.
Examining the overall spending in Nepal, we note that
US$ 24.5 million was spent on HIV/AIDS. Of this total
spending, 90% came from external sources and 10%
from domestic sources [26]. Although there are supports
from donors, NGOs (Non-Governmental Organisations)/
INGOs (International Non-Governmental Organisations)
and governments, HIV-affected households are still
paying a significant amount of money for their HIV
positive family member’s treatment and care - for
example, for travel, diagnostic tests, medicines other
than ART, lodging and food. Support from the govern-
ment is limited to CD4 (Cluster of Differentiation four)
test and ART medicines. A study report also
highlighted travel cost as a major problem and reported
that the HIV-affected households were facing financial
constraints for HIV/AIDS treatment in Nepal [27].
There were few studies conducted on the direct
costs to the households, but there were no studies
which reported the productivity costs due to HIV/
AIDS in Nepal. A review reported that there were no
sufficient research on economic issues of HIV/AIDS
in Nepal [19]. Only two studies assessed the direct
costs of HIV/AIDS treatment [28, 29]. Nevertheless,
these studies did not include all the components of
treatment costs, and did not cover rural areas. There
were no studies in Nepal reporting on actual product-
ivity costs caused by HIV/AIDS, and determinants of
direct and productivity costs [19]. Therefore, there
has been a knowledge gap concerning these issues in
the Nepalese context. The ‘cost of illness’ study pre-
sented below was conducted to explore in detail the
economic burden of HIV/AIDS from the household’s
perspective, in terms of direct costs and productivity
costs, and to establish some determinants of these
costs.
Methods
This is a cross-sectional study that employed a quantita-
tive approach to collect information. A face-to-face
structured survey obtained information from the respon-
dents. In 2011, there were 23 HIV treatment and care
centres in Nepal. Out of these, six treatment and care
centres from six districts were selected purposively,
based on their coverage, location and accessibility. These
centres were: BP Koirala Institute for Health Sciences,
Dharan, Sunsari; Sukraraj Tropical and Infectious
Diseases Hospital, Teku, Kathmandu; Bharatpur Hospital,
Bharatpur, Chitwan; Rapti Sub-Regional Hospital, Dang;
Bheri Zonal Hospital, Nepalgunj, Banke; and District
Hospital, Silgadi, Doti.
Sample size, sampling process and data collection
A total of 446 respondents were approached and 415
respondents agreed to participate in the survey (93%
response rate). The source of information for the sur-
vey was PLHIV aged 18 or over and who had been
diagnosed HIV positive more than a month prior to
the survey. The PLHIV who came to the treatment
centres for check-ups, counselling and medicines were
accessed for the study. A purposive sampling method
was employed to select the participants for easy re-
cruitment and the active participation of the respon-
dents in the research [30].
A survey questionnaire was used to collect data from
the respondents (please see the Additional file 1). The
questionnaire was prepared in the English and Nepali
but face-to-face administration of the questionnaires was
in Nepali. After completion of the surveys, the collected
information was translated into English. Questionnaires
were piloted and validated by conducting an initial study
with 36 respondents. The main survey was conducted in
2011. The information from PLHIV was collected by the
researcher with the help of local assistants. The re-
searcher trained the local assistants in the field. The
Interviewer Manual was prepared and given them to
read first. The assistants were also observed, monitored
and supported while they were conducting first few sur-
veys to ensure the accuracy of the data, and consistency
of interview style by the interviewers. The respondents
who visited the HIV treatment and care centres were re-
cruited for the study were asked to provide details of
costs of HIV treatment to avoid possible under estima-
tion of costs, since some patients also went to private
clinics or hospitals for their treatment. The given infor-
mation was crosschecked and edited immediately follow-
ing the interview; and collected data were crosschecked
afterwards by the researcher prior to the analysis.
This research was approved by Nepal Health Research
Council (NHRC) (a government ethical approval body), the
National Centres for AIDS and STD Control (NCASC),
and the University of Aberdeen, UK. Informed consent
was taken from the respondents before starting the sur-
vey. Anonymity and confidentiality were maintained
throughout the research process from the data collec-
tion to the report dissemination phase. The collected
information was solely used for the purpose of the
study and kept confidential. No cash payment was
made to the participants, in order to avoid ‘bias’ in the
over-eager volunteering of information simply to please
the researcher. This research has fully considered the
ethical procedures at all stages of its research processes.
Data analysis
Data obtained from the survey was entered into the
SPSS version 20 spreadsheet, and after that coded and
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cleaned for analysis purposes. Data analysis was done
using descriptive statistics - mainly means, standard de-
viation, frequencies, and percentages; and regression
analyses. Measurement methods for direct costs, producti-
vity costs and total costs are described below.
Measurement of average total direct cost
Direct costs in this study was measured from the house-
hold’s perspective that means household was the payer.
Average total direct costs for HIV/AIDS treatment were
measured by combining all the average out-of-pocket
medical and non-medical costs for HIV infected indi-
viduals, as well as costs for accompanying person/s.
These included costs of doctors, diagnostic tests, clinic
or hospital charges, travel, food, lodging and other
items at the time of treatment. Direct costs incurred for
accompanying person/s attending for diagnosis and/or
treatment were included in the measure of average total
direct costs. In Nepal, PLHIV under ART medicine
need to visit a HIV/AIDS treatment and counselling
centre every month for treatment, routine check-up
and counselling services. In addition, while conducting
the survey, it was found that PLHIV who were not
under ART also visited clinics, hospitals or treatment
centres every month to see doctors to check their general
health, and treat non-HIV major and minor illnesses
(which nevertheless, may have been indirectly caused by
immune system deficiency). Therefore, the direct cost for
the last visit to the treatment centre was taken to be
equivalent to the monthly direct costs due to HIV/AIDS
in this study.
Measurement of average productivity cost
In this study, productivity cost was defined as the inability
to carryout normal daily activities (paid and or unpaid
work), and their valuation. Normal daily activities were
defined as formal and non-formal work carried out by in-
dividuals in rural and urban settings.
To calculate the productivity losses, the inability of
PLHIV was divided into absenteeism and presenteeism.
Complete inability to carry out normal daily activities due
to illness was defined as ‘absenteeism’, and ‘presenteeism’
was defined as reduced work efficiency due to ill
health while still working. The sum of absenteeism
and presenteeism was termed as ‘productivity losses’
and their monetary valuation was termed as ‘productivity
cost’ in this study. To calculate the productivity losses due
to presenteeism, two aspects were taken into account: the
period during which losses were experienced and the ex-
tent to which work efficiencies were affected. To calculate
the respondent’s days lost due to illness, respondents were
asked whether they were completely unable to work in the
last 2 months (60 days) or not. A visual analogue scale
(VAS) ranging from blocks zero (0) to five (5) was used in
asking individuals about work efficiency when they were
ill but still working. Block zero meant ‘unable to work at
all’, block one meant ‘one out of five efficiency’, and so on.
Block five (5) meant illness did not affect work efficiency
at all. Therefore, respondents would never answer block
one or block five if they worked in a state of ill-health,
because block zero means absenteeism and block five
meant ‘not sick at all’. To calculate the days lost due to
presenteeism, the total days worked in a state of poor
health was multiplied by the inefficiency of the work
during ill health.
The days recovered were also calculated in the same
way by using a VAS as presenteeism. Firstly, respondents
were asked whether they got help or not from others
when they were ill. If they said ‘no’, then the days re-
covered would be zero (0). If they said ‘yes’, then they
were asked on how many days they got help. To oper-
ationalise this, they were asked on a VAS with blocks
of zero to five, how much work was completed by
others helping. To calculate the days recovered from
other’s help, the days helped by others were multiplied
by the amount of work done by other’s help. Although
respondents were asked the total days lost due to HIV/
AIDS (absenteeism and presenteeism) in the last 2-month
period, the total days lost were divided into two, to get
monthly days lost due to HIV/AIDS. Thus, in this study,
total days lost due to HIV/AIDS before adjustment of
coping strategies (sum of absenteeism and presenteeism),
total days recovered by other’s help, and days lost after
adjustment by coping strategies were calculated.
Valuation of productivity losses in this study was done
by using per capita gross domestic product (GDP) of Nepal
(NRs 142.8/day, according to World Bank for 2011).
Valuation using per capita GDP was preferred, because this
approach values time loss of rich or poor people by an
average for the whole society: it is not appropriate to value
rich people’s time at a high rate and poor people’s time at
low rate. It is specifically true for HIV/AIDS which unlike
other diseases like malaria is not a disease of rich or poor;
it affects both rich and poor alike. Likewise, productivity
costs ‘before coping strategies’, is preferred rather than
‘after coping strategies’, since coping strategies do not make
productivity costs disappear. As the name implies, these
strategies simply allow people to cope better. Therefore,
productivity costs before coping strategies, were valued by
using per capita GDP, and was preferred over productivity
costs after coping strategies.
The total costs in this study were calculated by sum-
ming the average total direct costs to the household, and
the productivity costs in a monthly period.
Regression analysis
In this study, regression analyses were conducted to find
the important predictor variables for treatment and
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access costs for PLHIV (as the direct costs), and producti-
vity costs before coping strategies. Regression analyses for
total direct costs to the household were not conducted
because PLHIV who took an accompanying person ob-
viously need to pay higher costs because of the addi-
tional costs required for the accompanying person/s.
This might overshadow the impact of other important
variables like the health status, and the income level of
the PLHIV. Therefore, regression analyses for treat-
ment and access costs in the place of total direct costs
were used.
To conduct the regression analyses for treatment and
access costs and productivity costs, the predictor vari-
ables which were significant to the relevant outcome
variables in the descriptive analyses, were taken into
consideration. Occupation, ethnicity, CD4 level, self-
reported health status, PLHIV accompanied or not,
household income and study district were found to be
statistically significant variables for the direct costs in
the descriptive statistics. Likewise, education, occupa-
tion, ethnicity, CD4 level, self-reported health status,
PLHIV accompanied or not, and study district were
found significant variables for productivity costs in de-
scriptive statistics. As the health status was measured in
two forms: self-reported health status and CD4 level, one
regression with self-reported health status and another re-
gression with CD4 level were conducted separately along
with other significantly contributing variables. Likewise,
household income was also presented in two forms: as a
continuous variable, and in income quintiles; one regres-
sion with income (as a continuous variable) and another
regression with income quintiles were conducted separ-
ately along with other significantly contributing variables.
Thus, four different types of regression analyses for treat-
ment and access costs and three regression analyses for
productivity costs were conducted before conducting the
tests (here test regression analysis means the analysis
which was conducted to test the significant of other extra
variables which did not show up as significant in the
descriptive analyses for the outcome variable); and then,
final regression analyses. After that, a number of separate
regression analyses were conducted to check if the other
variables which did not contribute significantly in the de-
scriptive analyses did emerge significantly as synergistic,
or interactive variables. After checking all results, a final
list of significantly contributing predictor variables was
prepared and used for the final, reduced form of regres-
sion analysis.
Before conducting the regression analyses, normality,
linearity, multicolinearity, and outliers among the vari-
ables were checked. Normality and linearity were checked
by using histogram and normal probability plot, multicoli-
nearity was checked by using Pearson correlation, and
outliers were checked by using Mahalanobis and Cook’s
distance matrices. To correct the skewed data, log trans-
formation (log10) was made for treatment and access
costs, productivity costs (before coping strategies) and
household income. All other variables which were either
interval or nominal in nature, were rescored as binary
variables. Examples of potential predictors which were
changed into binary or dummy variables were: study dis-
tricts, education of PLHIV, occupation of PLHIV, ethnicity
of PLHIV, CD4 level of PLHIV, self-reported health status
of PLHIV, and PLHIV accompanied with other.
As our outcome variables were log transferred and
some of the predictor variables were also log transferred,
the regression equation was:
LogY ¼ αþ b1X1 þ b2logX2 þ b3X3
þ…………:: þ bkXk þ e−−−−−−− ð½1Þ
Where,
Log Y = outcome variable (log transferred)
X1, X2, X3, and Xk are predictor variables
α represents regression constant or intercept
b1, b2, b3, and bk are the unstandardized regression
coefficients, where k represents the number of predictor
variables, and e is the error.
In the above regression equation, predictor variable X2
is log transferred.
Results
Basic information on respondents
Out of 415 respondents surveyed, 50.6% were male and
93.3% were aged 18 to 49 years (mean 36 years). Almost
64% of respondents were from rural areas and 66% were
literate (informal to higher level of education).
More than 25% of respondents were farmers, 45.8%
were Brahmin/Chhetri and 94.5% were heterosexual.
More than 67% of respondents were married; 79.5%
were taking ART, and 46.5% were with CD4 level
between 200/mm3 to 400/mm3. Around 58% of respon-
dents had self-reported good health status, and 29.2% of
respondents were accompanied by a family member,
friend or relative while visiting the treatment centre.
Although the insurance system in Nepal does not cover
HIV positive people, five out of 415 respondents re-
ported that they had health insurance, but never used
insurance support for their treatment (Table 1).
Average direct cost for HIV/AIDS treatment
It was found that the average direct costs to the HIV-
affected household at the last visit to the treatment
centre (including accompanying person) was NRs 1512
(US$ 20.4), which was 19.3% of the average household
income (NRs 7837). Average treatment costs for HIV/
AIDS on the last visit was NRs 922 (US$ 12.5), which
was 61% of the average direct costs for the last visit. The
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highest treatment costs was accounted for by the cost
for diagnostic tests (NRs 486.7, or US$ 6.6) (32.2%)
followed by cost of medicine (NRs 313 (US$ 4.2)
(20.7%). Average access costs for PLHIV on the last visit
were found to be NRs 445.4 (US$ 6), which is 29.4% of
average direct costs for the treatment on the last visit.
Among the access costs, transportation costs accounted
18.5% of the average direct costs. Thus, total treatment
and access costs for PLHIV on the last visit was NRs
1367.5 (US$ 18.5), which is 90.4% of the average direct
costs for the last visit. The costs for accompanying
person/s accounted for 9.6% of the average direct costs
(NRs 144.5) (Table 2).
While looking at the total direct costs of treatment per
visit based on CD4 counts, significantly higher costs
were experienced by the PLHIV who had CD4 counts
equal to or less than 200/mm3 (NRs 2051.7) compared
to the PLHIV who had CD4 counts more than 200/mm3
(NRs 1319.5) (p < 0.001).
Average productivity cost due to HIV/AIDS
The study found that the average number of days on
which a PLHIV was completely unable to carry out nor-
mal daily activities (absenteeism) in a month was 3.15,
Table 1 Socio-economic characteristics of the survey
respondents
Characteristics Frequency (N) Percentage (%)
Study Districts (Treatment centres)
Sunsari 60 14.5
Kathmandu 105 25.3
Chitwan 70 16.9
Dang 60 14.5
Banke 60 14.5
Doti 60 14.5
Gender
Male 210 50.6
Female 205 49.4
Age Group of Respondents
18 to 49 years 387 93.3
≥50 years 28 6.7
Location of the Respondents
Rural 265 63.9
Urban 150 36.1
Educational Status
Illiterate 141 34.0
Primary/informal class
(can read & write)
146 35.2
Secondary/under SLCa 89 21.4
Above SLC 39 9.4
Main Occupation
Employed/having job 97 23.4
Business/self employed 62 14.9
Agriculture 107 25.8
Household work 45 10.8
Unemployed 50 12.0
Wage labour 28 6.7
Other (student/retired/handicapped
or very weak)
26 6.3
Ethnicityb
Brahmin/Chhetri 190 45.8
Newar/Gurung/Thakali 38 9.2
Other Ethnic Groups 109 26.3
Dalits 57 13.7
Madeshi Tribes 21 5.1
Sexual Orientation
Heterosexual 392 94.5
Lesbian/Gay/Bisexual/Transgender 23 5.5
Marital Status
Married 280 67.5
Widow/widower 100 24.1
Unmarried/Divorced/Separated 35 8.4
Table 1 Socio-economic characteristics of the survey
respondents (Continued)
Having ART or Not
Having ART 330 79.5
Not Having ART 85 20.5
Current CD4 Level
>400/mm3 113 27.2
200–400/mm3 193 46.5
<200/mm3 109 26.3
Current Health Status
Good 243 58.6
Medium 138 33.3
Poor 34 8.2
Respondents with accompanying person
Yes 121 29.2
No 294 70.8
Having Health Insurance
Yes 5 1.2
No 410 98.8
aSLC means School Leaving Certificate, it is the same as a class ten pass.
The students who pass class ten get this certificate which is required to get
admission to college level
bIn this study, caste systems are defined as ethnicity. There are five major
castes in Nepal. Brahmin/Chhetri is the highest caste followed by ethnic
groups. Ethnic groups are also divided into two: Newar/Gurung/Thakali as the
well-off ethnic castes and other ethnic groups who are less well-off than
Newar/Gururng/Thakali. Dalit are the most marginalised caste in Nepal and
Madeshi Tribes are ethnic minorities who lives in Terai part of Nepal
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and average days lost while present at work in a state of
poor health with reduced efficiency (presenteeism) in a
monthly period were 1.9. Therefore, average productivity
loss before adjustment by coping strategies in a monthly
period was 5.05 days. Average total days recovered by
others’ help was 1.45. After adjustment by coping
strategies (i.e. subtracting days recovered by others help
from the total days lost), average total days lost due to
HIV/AIDS in a monthly period was 3.6. Here, coping
strategies indicate the support from other people like
family members, relatives, neighbours or friends who
help the PLHIV for their care and any kind of work in-
cluding household work.
Average productivity costs were calculated by multi-
plying average days lost due to HIV/AIDS in a monthly
period with the per capita GDP of the country in 2011.
Through valuing productivity losses before adjustment
of coping strategies, and after adjustment of coping
strategies, two figures of productivity costs were ob-
tained. Thus, average productivity costs due to HIV/
AIDS in a monthly period before and after adjustment
by coping strategies were NRs 721 (US$ 9.7) and NRs
514 (US$ 6.9) respectively.
The proportion of productivity costs valued by per
capita GDP before adjustment of coping strategies was
9.2%, and after adjustment for coping strategies was
6.6% of the average household income. While looking
at the productivity costs before adjustment of coping
strategies based on CD4 counts, the higher proportion
was accounted for by PLHIV who had CD4 counts
equal or less than 200/mm3 (NRs 1157.2/month) than
the PLHIV who had CD4 counts more than 200/mm3
(NRs 565.7/month) (p < 0.001) (Table 3).
Average total costs due to HIV/AIDS (direct costs and
productivity costs)
Average total costs were calculated by adding the aver-
age total direct costs to the household due to HIV/AIDS
at the last visit to the treatment centre with the average
productivity costs due to HIV/AIDS in a monthly
period. Average total costs due to HIV/AIDS for a
month’s period were calculated by summing the average
direct costs, and the average productivity costs due to
HIV/AIDS in a monthly period.
Thus, average total costs due to HIV/AIDS before
coping strategies by using the per capita GDP for valu-
ation was NRs 2233 (US$ 30.2), which was 28.5% of the
average household monthly income. The proportion of
average total direct costs was 67.7% of the total costs of
the HIV/AIDS (NRs 1512 of NRs 2233), and the propor-
tion of average productivity costs to the average total
costs was 32.3% (NRs 721 of NRs 2233).
Determinants for treatment and access costs
The final reduced form of regression analysis (Table 4)
showed that household income (log), the health status of
PLHIV (CD4 level), occupation, PLHIV accompanied or
not, and study district were the significant predictor
variables. Specifically, household income (log) (p < 0.001),
CD4 level 200–400/mm3 (p < 0.01), CD4 level <200/mm3
(p < 0.001), Kathmandu district (p <0.001) and PLHIV ac-
companied by others (p < 0.001) contributed positively to
the treatment and access costs, but ‘household work’ as an
occupation (p < 0.05) contributed negatively.
The final regression analysis for the treatment and ac-
cess costs (log) showed that the expected increase in
treatment and access costs was 3%, with an increment of
household income of 10%, holding other variables con-
stant. The expected increase in treatment and access
costs from CD4 level >400/mm3 to 200–400/mm3 was
20.3%, holding other variables constant. The expected
increase in treatment and access costs from CD4 level
>400/mm3 to <200/mm3 was 30.3%, holding other
variables constant. The expected increase in treatment
and access costs from the Doti district to the Kathmandu
district was 24.7%, holding other variables constant. The
expected increase in treatment and access costs from
PLHIV unaccompanied to PLHIV accompanied by others
was 16.6%, holding other variables constant. The expected
decrease in treatment and access costs from agricultural
occupation to household work was 17%, holding other
variables constant (Table 4).
The regression analyses confirm that household in-
come, health status of PLHIV (CD4 level), occupation of
PLHIV, PLHIV accompanied by others, and study district
were the important predictor variables of the treatment
and access costs. Thus, the treatment and access costs
were highest for PLHIV having the highest household
Table 2 Direct costs for the HIV/AIDS treatment at the last visit
to the treatment centre
Cost categories Average costs
in NRs
(Std. Deviation)
Percent of total
direct costs (%)
Cost of doctors 63.9 (126.3) 4.2
Cost of diagnosis or test 486.7 (720.0) 32.2
Cost of medicine 313.0 (627.5) 20.7
Other medical costs 58.5 (181.3) 3.9
Total treatment costs 922.1 (1324.2) 61
Cost of transportation 279.0 (365.5) 18.5
Food cost of patient 106.8 (232.0) 7.1
Lodging cost and other access costs 59.6 (209.2) 3.9
Total access costs 445.4 (630.2) 29.4
Treatment and Access Costs 1367.5 (1564.4) 90.4
Cost for accompanying person 144.5 (419.4) 9.6
Total direct costs 1512 (1813.2) 100
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income, PLHIV having CD4 level <200/mm3, PLHIV
coming to Kathmandu district for treatment and PLHIV
accompanied by others. The treatment and access costs
were lowest among the PLHIV with household work
occupation.
Determinants for productivity costs
Final reduced form of regression analysis (Table 5)
showed that health status, ethnicity, sexual orientation,
and study district were important predictor variables for
productivity costs. Specifically, self-reported medium
health status (p < 0.001), self-reported poor health status
(p < 0.001), Dalit (p < 0.01), LGBT (lesbian, gay, bisexual
and transgender) (p < 0.05), Sunsari district (p < 0.001),
Chitwan district (p < 0.001), Dang district (p < 0.001),
Banke district (p < 0.001), were positively contributing to
the productivity costs.
The final regression analysis for the productivity costs
(log) shows that the expected increase in productivity
costs from the Brahmin/Chhetri to the Dalit caste was
almost 29%, holding other variables constant. The ex-
pected increase in productivity costs from self-reported
good health status to self-reported medium health status
was 29.8%, holding other variables constant. The ex-
pected increase in productivity costs from self-reported
good health status to self-reported poor health status
was 128%, holding other variables constant. The ex-
pected increase in productivity costs from heterosexual
PLHIV to LGBT (lesbian, gay, bisexual and transgender)
PLHIV was 24.2%, holding other variables constant. The
expected increase in productivity costs from the Doti dis-
trict to the Sunsari district was almost 50%, holding other
variables constant. The expected increase in productivity
costs from the Doti district to the Chitwan district was
70.4%, holding other variables constant. The expected in-
crease in productivity costs from the Doti district to the
Dang district was almost 43%, holding other variables
constant. The expected increase in productivity costs from
Table 3 Average productivity losses and costs in a monthly period due to HIV/AIDS among PLHA
Items Average days lost
(Std. Dev)
Valuation by using per capita GDP in
2011 (NRs 142.8/day) (World Bank data)
(Average Productivity Costs)
Absenteeism (days completely unable to work) (A) 3.15 (6.96) 449.7
Presenteeism (days worked in poor health x reduced
efficiency) (P)
1.9 (3.22) 271.3
Productivity loss before adjustment of coping
strategies (A + P)
5.05 (7.62) 721
Days recovered by other’s help (total days help received x
amount of work done) (DROH)
1.45 (2.11) 207
Productivity loss after adjustment of coping strategies
[(A + P)–DROH)]
3.6 (6.03) 514
Table 4 Linear regression analysis for treatment and access
costs (log)
Final regression analysis reduced form
Predictor variables b SE
Kathmandu .221*** .057
Household work -.157* .078
CD4 level 200–400/mm3 .185** .059
CD4 level < 200/mm3 .265*** .067
Household income (log) .307 *** .076
PLHA accompanied by others .154** .054
Constant 1.473*** .292
No. of observations 410
R-square 0.136
Adjusted R-squire 0.123
p value 0.000
b means coefficient and SE means standard error, *p < 0.05,
**p < 0.01, ***p < 0.001
Table 5 Linear regression analysis for productivity costs before
coping strategies (log)
Final regression analysis reduced form
Predictor variables b SE
Sunsari .405*** .070
Chitwan .533*** .066
Dang .357*** .072
Banke .321*** .070
Dalit .254*** .066
Self-reported medium health status .253*** .051
Self-reported poor health status .824*** .084
LGBT .217* .099
Constant 2.246 .046
No. of observations 314
R-square 0.413
Adjusted R-square 0.397
p value 0.000
b means coefficient and SE means standard error, *p < 0.05,
**p < 0.01, ***p < 0.001
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the Doti district to the Banke district was almost 38%,
holding other variables constant (Table 5).
Thus, productivity costs were highest among PLHIV
in the Chitwan district, Dalit caste, self-reported poor
health status and among LGBT.
Discussion
Average total direct costs to the HIV-affected household
(NRs 1512 or US$20.4 per visit) for HIV/AIDS treat-
ment in our study were higher than other studies on
HIV/AIDS conducted in Nepal [28, 29]. Higher direct
costs in our study were due to inclusion of all costs
components and various geographical locations, avail-
ability of better but expensive diagnostic and treatment
facilities in the private and government hospitals in re-
cent years, and higher awareness levels among PLHIV
than before. The average total direct costs for HIV treat-
ment in our study were higher than reported for tuber-
culosis, water borne diseases and malaria treatment in
Nepal [31–33]. However, we cannot compare other
studies in Nepal with costs of kala-azar (visceral leish-
maniosis or VL) [8, 34], and hepatitis E treatment [35]
because of methodological differences in calculation of
the costs.
Our study findings show that the highest proportion
of direct costs was accounted for by diagnostic tests
(32.2%). There is difference between costs of treatment
(i.e. doctor’s fee, diagnostic tests, medicines etc.) in
government hospitals and private clinics or hospital. The
treatment costs increase significantly if the PLHIV visits
to the private clinics or hospitals. Although the PLHIV
suspect that they might have HIV, they do not visit the
hospital or clinic until they are very ill because of pos-
sible discrimination from families, relatives and society.
This further helps to increase the costs of treatment.
Access costs accounted for the second highest propor-
tion (29.4%) of direct costs. There are no HIV/AIDS
treatment and care services in every district of Nepal,
meaning some PLHIV need to travel farther resulting
into higher access costs. A previous study also men-
tioned the distance from health care facilities as a main
problem in getting HIV/AIDS treatment services in
Nepal [27]. Moreover, there are no insurance facilities
for PLWA in Nepal, which forces individuals to pay out-
of-pocket for their treatment. This puts the majority of
HIV-affected families at risk of falling into ‘the poverty
trap’.
In our study, HIV-affected households spent more
than a five times higher proportion of household income
for HIV/AIDS (19.3%) than reported by the government
of Nepal for general health care (3.3% of average house-
hold income) [36], even though nearly half of the sample
households (47.2%) were living in poverty, compared to
the general population figure (25%). This evidence shows
that HIV-affected households pay a considerably higher
proportion of their income on healthcare compared to
the general population.
While comparing our study findings with similar studies
conducted in other countries, the average total direct costs
of HIV/AIDS treatment in our study is similar to the total
median costs in South India [4] and comparable to
Vietnam [20] and Malaysia [37]. However, a study in Chad
reported the average total costs more than four times
higher than those found in our study [13]. The lower aver-
age direct costs in our study compared with the findings
in Chad were mainly due to inclusion of both AIDS and
non-AIDS respondents. However, a study conducted in
Benin reported almost half the costs to access the package
of care for ART therapy, than those from our own study
findings [38]. The higher direct costs in our study than
the study in Benin may be due to methodological dif-
ferences, as they assessed the costs only to get ART
medicine, unlike in our study.
Average total productivity losses (absenteeism and
presenteeism) due to HIV/AIDS before adjustment for
coping strategies in Nepal was found to be very high in a
monthly period (5.05 days). Per month absenteeism (days
completely unable to carry out normal daily activities) was
3.15 days and presenteeism (days lost due to reduced
working efficiency because of poor health) was 1.9 days.
Productivity costs before adjustment for coping strate-
gies by using per capita GDP for valuation was NRs
721 (US$9.7) per month, which was 9.2% of the aver-
age monthly household income. The proportion of
productivity costs to total costs (sum of direct costs
and productivity costs) before adjustment of coping
strategies was 32.3%, when doing a valuation using per
capita GDP (NRs 721 of NRs 2233).
There have been no studies conducted in Nepal, which
measured productivity losses due to HIV/AIDS. The
findings of the studies on kala-azar (VL) [34, 39], hepa-
titis E [35] and malaria [33] could not be compared be-
cause of methodological differences in calculating days lost,
since these studies calculated costs on a per episode basis.
We note that studies related to productivity losses
due to HIV/AIDS in other countries, studies in India
[4] and Malaysia [40] reported lower productivity losses
than were found in our study. The productivity losses
among AIDS patients reported in Chad [13] is compar-
able to the productivity losses among PLHIV with a
self-reported poor health status in our study. The
higher productivity losses in our study might be for two
reasons. Firstly, PLHIV in Nepal do not have access to
a balanced diet required to keep them healthy, due to
their chronic poverty. This may weaken their immune
system, making them more vulnerable to opportunistic
infections. Secondly, we also included presenteeism in
productivity losses unlike other studies [4, 40].
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Average total costs (sum of average total direct costs
and average productivity costs before adjustment of
coping strategies, by using per capita GDP for valuation)
due to HIV/AIDS in Nepal was NRs 2233 (US$ 30.2),
which was 28.5% of an average household monthly in-
come. There were no studies in Nepal assessing the per
month average total cost of HIV/AIDS to compare to
our study. The average total costs due to HIV/AIDS in
our study are considerably higher compared to other
diseases in Nepal, because of its chronic nature. Other
diseases like tuberculosis, kala-azar (VL), hepatitis E,
and malaria can be healed through treatment; therefore,
HIV/AIDS causes a higher and long-term economic bur-
den on the HIV-affected households than is caused by
the above-mentioned diseases.
Looking for studies similar to our own, we found
few that had developed a complex methodology of
measuring economic costs that could be compared
with our results. One study in Chad reported the total
cost for AIDS care to be considerably higher than our
study finding. However, they studied only AIDS pa-
tients (a more serious stage of HIV/AIDS), and in-
cluded funeral costs in their study. A study in Spain
reported total costs of care for asymptomatic HIV,
symptomatic HIV and AIDS patients to be relatively
higher than the total costs found in our study [41].
In our study, treatment and access costs (in terms of
direct costs) were significantly determined by the
health status of respondents (CD4 level 200–400/mm3 –
p < 0.01, CD4 level <200/mm3 – p < 0.001), household in-
come (p < 0.001), occupation of respondents (p < 0.05),
respondents accompanied by others (p < 0.01) and study
district (p < 0.001).
As mentioned above, the CD4 level as a measure of
the health status of respondents was found to be one of
the significant predictor variables for the treatment and
access costs. The respondents with lower CD4 level had
to pay higher treatment and access costs compared to
respondents with a higher CD4 level. This finding is
supported by the studies conducted in in India [4], Italy
[42] and Spain [41]. Another significant predictor vari-
able for the treatment and access costs was household
income. Respondents having a higher household income
paid higher treatment and access costs. This finding was
supported by a study in India [4]. Occupation was found
to be another significant predictor variable for the treat-
ment and access costs. The respondents with household
work as their occupation had paid significantly lower
treatment and access costs than the respondents with
agriculture (farming) as their occupation. The descrip-
tive analysis shows that respondents with an agriculture
occupation paid higher access costs than respondents
with household work as their occupation. This evidence
suggests that respondents with an agriculture occupation
travel further for their treatment, resulting in higher treat-
ment and access costs. Study district and PLHIV accom-
panied by others were found to be other significant
predicator variables for treatment and access costs, the
reason being that respondents who need to go far for their
treatment generally took an accompanying person. Like-
wise, respondents travel farther for the better treatment
facilities which are not available in their local area. There-
fore, longer travel distance and use of better treatment fa-
cilities increased the treatment and access costs for
respondents who took an accompanying person them.
The health status of respondents was a significant pre-
dictor variable for productivity costs. This finding is also
supported by studies from India and Switzerland [4, 43].
Ethnicity was found to be another significant predictor
variable for the productivity costs. Dalit (lower class) re-
spondents had higher productivity costs than Brahmin/
Chhetri respondents. The reason may be their poor
economic status, as they cannot afford healthy diet, or
timely treatment, which require them to fight against
infections. Sexual orientation was also found to be a
significant predictor variable for productivity costs.
Productivity costs were higher for LGBT (lesbian, gay,
bisexual and transgender). The reason may be related to
the risky behaviour (e.g. - injecting drugs) adopted by
the LGBT respondents. It has been reported that sub-
stance abuse is seven times higher among LGBTs than
heterosexuals [44]. Use of serious drugs may be one of
the most important factors to increase productivity
losses among LGBTs. This argument is indirectly sup-
ported by a study in Switzerland, which reported intra-
venous drug use as the important determinant of
productivity costs among PLHIV [43]. Study district was
another important predictor variable for productivity
costs. The variation in productivity losses by study site
has been supported by other studies [39, 45].
Surprisingly, income was not a significant predictor
variable for the productivity costs. It was found that
productivity losses between the poorest respondents
(first income quintile) and the richest respondents (fifth
income quintile) were almost the same (5.5 days vs
5 days). The poorest PLHIV may be sicker than the
richest PLHIV due to the unaffordability of treatment
in time and lack of a nutritious diet. However, they
have to work every day for their own and their family’s
livelihood, although they are sick [46]. Perhaps, the
richest respondents may be less sick than the poorest re-
spondents (due to affordability of treatment in time or
better diet), or they can afford to take time off to be sick.
This is the first study of its kind in Nepal. The sample
of the study is also representative of Nepal’s population.
This is because it has a relatively large sample size
(>400), and was conducted in six representative districts
of Nepal, which cover five development regions, east to
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west, and hilly and mountainous to Terai (the plains) re-
gions of the country. In addition, the study included
both rural and urban areas unlike previous studies,
which were focussed only in urban areas. While calculating
costs of illness, previous studies had excluded some im-
portant cost components like ‘costs for accompanying
person’ in attempting to calculate direct costs, and cost of
presenteeism in calculating productivity costs. Our study
has included all components of the direct costs and
productivity costs.
This study was conducted in government operated
HIV/AIDS treatment centres. Therefore, it excluded
those PLHIV who did not visit the treatment centre
during the period of the study. Due to the limitations of
time and resources, control groups (e.g. - HIV negative
people, or people with other disease profiles) were not
accessed. Cross-sectional studies only capture informa-
tion from respondents at a certain point of time when
data collection is carried out. Therefore, information col-
lected in cross-sectional studies may not be as robust as
information collected from longitudinal studies because
variations in study subjects may be affected by weather,
seasons and time of study. Most of the data in the study
were derived from reporting of respondents who needed
to recall their past. Therefore, there might be a possibility
of recall bias by respondents about the given information
and uncertainty about the robustness of the data. More-
over, the data in the study was collected in 2011. There
might be changes in costs and burden to the HIV-affected
households now due to changes in socioeconomic factors
affecting the burden over the period.
Conclusions
Although the doctor’s fees and medicine costs in the
government hospitals in Nepal are minimal, the HIV-
affected households are still paying a considerable
amount of money (relative to their incomes) for diagnos-
tic tests, transportation, food and lodging. Therefore, the
Government of Nepal should make a policy for the afford-
able and accessible treatment of HIV/AIDS for everyone.
It is recommended that the economic burden of HIV/
AIDS could be reduced by decentralising HIV/AIDS re-
lated services to district level and putting in place more
comprehensive service delivery for HIV/AIDS care, sup-
port and treatment.
Subsidies should be provided from both private and
governmental hospitals for the diagnostic tests for those
PLHIV who come from remote rural areas, who have
below poverty line income and who are marginalised
(such as rejected PLHIV from family or community and
being an impoverished widow/widower). Allowances
should be provided to marginalised PLHIV, similar to
the government current policy for pregnant women at
the time of delivery. This policy would not only reduce
the economic burden of PLHIV, but also encourage
them to go for HIV testing, with adherence to the ART
medicine. Early diagnosis means early treatment, lesser
costs for treatment and loss of productivity.
As the monthly direct costs and productivity losses are
very high compared to other diseases, the HIV-affected
household faces a considerable economic burden. PLHIV
often have limited occupational skills and experience re-
ducing their chances of economic independence. There-
fore, we advocate that the Government of Nepal should
establish a fuller policy to provide livelihood support
(skill development and income generating programmes)
for the PLHIV and their family members. The Government
of Nepal could provide health insurance to HIV-infected
people of as in Merauke, Indonesia.
To implement all of these policies, there would need
to be a larger budget for HIV/AIDS. This seems justified
from the results of this study showing that HIV/AIDS
exerts a greater economic burden on HIV-affected
households than other diseases. More focus and support
should also be given to those PLHIV who come from re-
mote rural areas, who are below the poverty line income,
and who are marginalised due to the disease, and their
community reactions.
In order to expand the knowledge of the economic
burden experienced by PLHIV, further study of the eco-
nomic impacts of HIV/AIDS upon the isolated, rejected,
widow, widower and separated PLHIV (from family and
society due to the disease) and the impact of HIV/AIDS
affected households’ children’s education is recommended.
In-depth knowledge of these issues would be beneficial in
order to formulate a proper policy to enhance the quality
of life for such individuals and their families. Likewise, we
recommend conducting a longitudinal study for a 6-
month period, including a control group to compare the
different variables under investigation, involving all types
of PLHIV from rural and urban areas.
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